Zepbound multi-dose KwikPen to be preferred on formulary starting August 1, 2026

CarelonRx is making changes to the DMHC National and Essential formularies. As of August 1, 2026, the Zepbound multi-dose KwikPen will be preferred for fully insured large group clients on the California DMHC National and Essential formularies. The Zepbound single-dose auto injector will move to non-formulary. There will be no grandfathering for this change.

• Any new Zepbound user after August 1 must obtain a prior authorization and prescription to align with this formulary change.
• Members currently using the single-dose auto-injector must transition to the multi-dose KwikPen by October 1.
• Members with a current prior authorization that ends before October 1 will need a new PA through the standard process when that authorization terms.
• Current users will be notified of this change via letter on August 1 and September 1.
• New prescriptions will be needed for the multi-dose KwikPen and pen needles. Prescribers will be notified of this change and will be asked to provide a new prescription.

If you have questions, please contact your Anthem or CarelonRx account representative.